Basilea Pharmaceutica International Ltd, Allschwil
Allschwil, BL
- UEI
- UA43HWRNXFS3
- CAGE
- SSU10
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Basilea Pharmaceutica AG, ranks:
- Self-certified in SAM.gov
- Entity structure
- Other
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- Hegenheimermattweg 167b, 4123 Allschwil, Switzerland
- Website
- basilea.com
- Founded
- 2000
- Employees
- 51-250
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $52,683,131 |
| FY2025 | $63,700,481 |
| FY2024 | $27,539,470 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $52,683,131 |
Contract awards
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Trustees Of Boston University | 75A50122C00028 | $9,053,709 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Venatorx Pharmaceuticals Inc. | Chadds Ford, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Melinta Therapeutics, LLC | Parsippany-Troy Hills, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Crestone, Inc. | Boulder, CO | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Curza Inc. | Salt Lake City, UT | — |
| Aimmax Therapeutics Inc. | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Basilea Pharmaceutica International Ltd, Allschwil, doing business as Basilea Pharmaceutica International SA, Allschwil, is a biopharmaceutical company specializing in the development of innovative antibiotics to combat multidrug-resistant bacteria, particularly gram-negative pathogens. Registered to receive awards from the U.S. federal government since February 8, 2013, Basilea has established itself as a key player in addressing urgent global health threats. The company focuses on developing novel treatment options for serious bacterial infections in hospital settings, including bloodstream infections, pneumonia, intra-abdominal infections, and urinary tract infections. Through federal contract and grant awards, Basilea has been engaged in advanced research and development of novel antibiotics, targeting high-priority pathogens identified by the Centers for Disease Control and Prevention and the World Health Organization.
Basilea's contract work primarily revolves around the development of antimicrobials for the treatment of resistant fungal and bacterial infections. The company has received a significant prime federal contract award from the Office of the Assistant Secretary for Preparedness and Response (ASPR), valued at $267,580,657. This definitive cost-sharing contract supports Basilea's work on a new class of antibiotics targeting the lipopolysaccharide transport system in gram-negative bacteria and inhibitors of an essential enzyme (DXR) not targeted by current antibiotics. Additionally, Basilea has been awarded federal contract sub-awards through the Trustees of Boston University. These sub-awards focus on developing novel antibiotics, including a new class targeting the lipopolysaccharide transport protein A (LptA) in gram-negative bacteria and inhibitors of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR). The company's contract work aims to address high-priority pathogens such as carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and multidrug-resistant Pseudomonas aeruginosa. These contracts are not set aside for specific business types, reflecting Basilea's competitive standing in the field.
In addition to its contract work, Basilea has received federal grant sub-awards for its antibiotic development programs, administered through the Trustees of Boston University as the prime grantee. The grant-funded research aligns closely with the contract work, focusing on the discovery and development of DXR inhibitors for treating infections caused by drug-resistant gram-negative bacteria. Basilea's grant-funded activities include hit-to-lead research, medicinal chemistry optimization, and the development of compounds with broad-spectrum antibacterial activity against high-priority pathogens. The ultimate goal of this research is to develop safe and effective treatment options for serious infections, particularly nosocomial respiratory tract infections, complicated intra-abdominal infections, and complicated urinary tract infections. This grant-funded work complements Basilea's contract-funded efforts, contributing to the company's comprehensive approach to addressing the global threat of multidrug-resistant bacterial infections. The grant program appears to be part of a broader initiative to combat antimicrobial resistance, likely funded by agencies such as the National Institutes of Health or the Biomedical Advanced Research and Development Authority (BARDA).
Quick answers
Is Basilea Pharmaceutica International Ltd, Allschwil registered in SAM.gov?
Yes. Basilea Pharmaceutica International Ltd, Allschwil's SAM.gov registration is active through March 10, 2027.
How much has Basilea Pharmaceutica International Ltd, Allschwil received in federal contracts?
Federal contracts obligated $63,700,481 to Basilea Pharmaceutica International Ltd, Allschwil in fiscal year 2025 and $143,923,082 in fiscal years 2023 through 2027.
How does Basilea Pharmaceutica International Ltd, Allschwil rank among federal contractors?
Basilea Pharmaceutica International Ltd, Allschwil's parent company, Basilea Pharmaceutica AG, ranked #4 in PSC AN42, #7 in NAICS 541714 and #11 in PSC AN in FY2025.
What is Basilea Pharmaceutica International Ltd, Allschwil's most recent federal award?
Basilea Pharmaceutica International Ltd, Allschwil's most recent federal contract award is The development of antimicrobials for the treatment of resistant fungal and bacterial infections - OTA (75A50124C00033), from Office of the Assistant Secretary for Preparedness and Response, on September 30, 2024.
On GovTribe
See Basilea Pharmaceutica International Ltd, Allschwil's full federal record
- Federal contract awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors